JOURNAL ARTICLE

Effects of BNT162b2 Messenger RNA Vaccine and ChAdOx1 Adenovirus Vector Vaccine on Deaths From COVID-19 in Adults Aged ≥70 Years.

  • Published In: Clinical Infectious Diseases, 2024, v. 78, n. 2. P. 349 1 of 3

  • Database: Academic Search Ultimate 2 of 3

  • Authored By: Bernal, Jamie Lopez; Andrews, Nick; Gower, Charlotte; Stowe, Julia; Tessier, Elise; Simmons, Ruth; Ramsay, Mary 3 of 3

Abstract

This article evaluates the risk of death from COVID-19 among symptomatic patients aged 70 years and older in England, comparing vaccinated and unvaccinated individuals. It finds that a single dose of the Pfizer-BioNTech BNT162b2 messenger RNA vaccine or the Oxford-AstraZeneca ChAdOx1 adenovirus vector vaccine reduces the risk of death by 44% and 55%, respectively, while two doses of BNT162b2 reduce the risk by 69%. The study also notes that vaccine effectiveness against death is higher than protection against infection alone and that the additional benefit of vaccination among care home residents was less clear for BNT162b2. These findings support prioritizing first-dose vaccination in vulnerable populations and completing the two-dose course for enhanced protection.

Additional Information

  • Source:Clinical Infectious Diseases. 2024/02, Vol. 78, Issue 2, p349
  • Document Type:Article
  • Subject Area:Business and Management
  • Publication Date:2024
  • ISSN:1058-4838
  • DOI:10.1093/cid/ciab881
  • Accession Number:175522636
  • Copyright Statement:Copyright of Clinical Infectious Diseases is the property of Oxford University Press / USA and its content may not be copied or emailed to multiple sites without the copyright holder's express written permission. Additionally, content may not be used with any artificial intelligence tools or machine learning technologies. However, users may print, download, or email articles for individual use. This abstract may be abridged. No warranty is given about the accuracy of the copy. Users should refer to the original published version of the material for the full abstract. (Copyright applies to all Abstracts.)

Looking to go deeper into this topic? Look for more articles on EBSCOhost.